GSGraham Starkey

Graham Starkey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Graham Starkey has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Meeting the demand: Incorporating living donor liver transplantation into the deceased donor liver transplantation landscape

    by Karl Vaz, Penelope Hey, Graham Starkey, Therese Bittermann, Maarouf A. Hoteit, Marcos V. Perini, Michael A. Fink, Avik Majumdar, Marie Sinclair, Adam Testro, et al.

    Liver transplantation (LT) has for decades been a well-established treatment for end-stage liver disease and malignancy, becoming the standard of care for select patients with these life-limiting conditions. Due to a limited pool of high-quality deceased donor organs, there is an existing and growing disparity between those in need of and those able to access LT. Living donor liver transplantation (LDLT) has emerged as one way to mitigate this disparity. Despite Australia’s place in history as the first reported LDLT from mother-to-child in 1987, living donation for adults is rare, in part due to perceived lack of need due to the historically low waitlist mortality data. This Perspective reviews the history of LDLT and utilises Australia as a case-study for exploring the necessity for LDLT in existing deceased donor liver transplant programs, the ethical considerations, risks and benefits of the procedure, and the means to implement LDLT.


  • Open Access

    Safety of apixaban prior to liver transplantation: A single-center Australian case-control study in a low MELD population

    by Katrina Tan, Zoe Yang, Elizabeth Low, Jordi Shahab, Jacqueline Balassone, Graham Starkey, Marcos Perini, Lachlan Miles, Adam Testro, Marie Sinclair, et al.


  • Open Access

    Selective regulation of IFN-γ and IL-4 co-producing unconventional T cells by purinergic signaling

    by Calvin Xu, Andreas Obers, Minyi Qin, Alice Brandli, Joelyn Wong, Xin Huang, Allison Clatch, Aly Fayed, Graham Starkey, Rohit D’cOsta, et al.

    Unconventional T cells, including mucosal-associated invariant T (MAIT), natural killer T (NKT), and gamma-delta T (γδT) cells, comprise distinct T-bet+, IFN-γ+ and RORγt+, IL-17+ subsets which play differential roles in health and disease. NKT1 cells are susceptible to ARTC2-mediated P2X7 receptor (P2RX7) activation, but the effects on other unconventional T-cell types are unknown. Here, we show that MAIT, γδT, and NKT cells express P2RX7 and are sensitive to P2RX7-mediated cell death. Mouse peripheral T-bet+ MAIT1, γδT1, and NKT1 cells, especially in liver, co-express ARTC2 and P2RX7. These markers could be further upregulated upon exposure to retinoic acid. Blocking ARTC2 or inhibiting P2RX7 protected MAIT1, γδT1, and NKT1 cells from cell death, enhanced their survival in vivo, and increased the number of IFN-γ–secreting cells without affecting IL-17 production. Importantly, this revealed the existence of IFN-γ and IL-4 co-producing unconventional T-cell populations normally lost upon isolation due to ARTC2/P2RX7-induced death. Administering extracellular NAD in vivo activated this pathway, depleting P2RX7-sensitive unconventional T cells. Our study reveals ARTC2/P2RX7 as a common regulatory axis modulating the unconventional T-cell compartment, affecting the viability of IFN-γ– and IL-4–producing T cells, offering important insights to facilitate future studies into how these cells can be regulated in health and disease.


  • Open Access

    mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis

    by Angus T Stock, Sarah Parsons, Jacinta A Hansen, Damian B D’SIlva, Graham Starkey, Aly Fayed, Xin Yi Lim, Rohit D’COsta, Claire L Gordon, Ian P Wicks

    The accumulation of myofibroblasts within the intimal layer of inflamed blood vessels is a potentially catastrophic complication of vasculitis, which can lead to arterial stenosis and ischaemia. In this study, we have investigated how these luminal myofibroblasts develop during Kawasaki disease (KD), a paediatric vasculitis typically involving the coronary arteries. By performing lineage tracing studies in a murine model of KD, we reveal that luminal myofibroblasts develop independently of adventitial fibroblasts and endothelial cells, and instead derive from smooth muscle cells (SMCs). Notably, the emergence of SMC-derived luminal myofibroblasts—in both mice and patients with KD, Takayasu’s arteritis and Giant Cell arteritis—coincided with activation of the mechanistic target of rapamycin (mTOR) signalling pathway. Moreover, SMC-specific deletion of mTOR signalling, or pharmacological inhibition, abrogated the emergence of luminal myofibroblasts. Thus, mTOR is an intrinsic and essential regulator of luminal myofibroblast formation that is activated in vasculitis patients and therapeutically tractable. These findings provide molecular insight into the pathogenesis of coronary artery stenosis and identify mTOR as a therapeutic target in vasculitis.


  • A systematic review and network meta-analysis of outcomes after open, mini-laparotomy, hybrid, totally laparoscopic, and robotic living donor right hepatectomy

    by Marcus Yeow, Shauna Soh, Graham Starkey, Marcos V. Perini, Ye-Xin Koh, Ek-Khoon Tan, Chung-Yip Chan, Prema Raj, Brian K.P. Goh, Tousif Kabir


  • Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles

    by Hyon-Xhi Tan, Jennifer A. Juno, Robyn Esterbauer, Hannah G. Kelly, Kathleen M. Wragg, Penny Konstandopoulos, Sheilajen Alcantara, Carolina Alvarado, Robert Jones, Graham Starkey, et al.

    Recent studies have established that memory B cells, largely thought to be circulatory in the blood, can take up long-term residency in inflamed tissues, analogous to widely described tissue-resident T cells. The dynamics of recruitment and retention of memory B cells to tissues and their immunological purpose remains unclear. Here, we characterized tissue-resident memory B cells (B RM ) that are stably maintained in the lungs of mice after pulmonary influenza infection. Influenza - specific B RM were localized within inducible bronchus-associated lymphoid tissues (iBALTs) and displayed transcriptional signatures distinct from classical memory B cells in the blood or spleen while showing partial overlap with memory B cells in lung-draining lymph nodes. We identified lung-resident markers, including elevated expression of CXCR3, CCR6, and CD69, on hemagglutinin (HA)– and nucleoprotein (NP)–specific lung B RM . We found that CCR6 facilitates increased recruitment and/or retention of B RM in lungs and differentiation into antibody-secreting cells upon recall. Although expression of CXCR3 and CCR6 was comparable in total and influenza-specific memory B cells isolated across tissues of human donors, CD69 expression was higher in memory B cells from lung and draining lymph nodes of human organ donors relative to splenic and PBMC-derived populations, indicating that mechanisms underpinning B RM localization may be evolutionarily conserved. Last, we demonstrate that human memory B cells in lungs are transcriptionally distinct to populations in lung-draining lymph nodes or PBMCs. These data suggest that B RM may constitute a discrete component of B cell immunity, positioned at the lung mucosa for rapid humoral response against respiratory viral infections.


  • A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity

    by Yannick O. Alexandre, Dominik Schienstock, Hyun Jae Lee, Luke C. Gandolfo, Cameron G. Williams, Sapna Devi, Bhupinder Pal, Joanna R. Groom, Wang Cao, Susan N. Christo, et al.

    A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity.


  • Open Access

    Outcomes for children after second liver transplantations are similar to those after first transplantations: a binational registry analysis

    by Angus W Jeffrey, Gary P Jeffrey, Michael Stormon, Gordon Thomas, Edward O'Loughlin, Albert Shun, Winita Hardikar, Robert Jones, John McCall, Helen Evans, et al.

    Objective To assess long term graft and patient survival after donor liver retransplantation in children in Australia and New Zealand during 1986–2017; to determine the factors that influence survival. Design Retrospective cohort analysis (registry data). Setting, participants Australia and New Zealand Liver Transplant Registry data for all liver retransplantations in children (under 18 years of age), 1986–2017, in all four paediatric and six adult liver transplantation centres in the two countries. Main outcome measures Graft and patient survival at one, 5, 10 and 15 years. Results 142 liver retransplantations were undertaken in children (59 during 1986–2000, 83 during 2001–2017). Kaplan–Meier survival analysis indicated that survival was significantly greater during 2001–2017 than 1986–2000 (P < 0.001). During 2001–2017, graft survival one year after retransplantation was 84%, at 5 years 75%, at 10 years 70%, and at 15 years 54%; patient survival was 89% at one year, 87% at 5 years, 87% at 10 years, and 71% at 15 years. Median time between transplantations was 0.2 years (IQR, 0.03–1.4 years) during 1986–2000, and 1.8 years (IQR, 0.1–6.8 years) during 2001–2017 (P = 0.002). The proportion of graft failures that involved split grafts was larger during 2001–2017 (35 of 83, 42%) than 1986–2000 (10 of 59, 17%). Graft type, cause of graft failure, and number of transplants did not influence survival following retransplantation. Conclusion Survival for children following retransplantation is excellent. Graft survival is similar for split and whole grafts. Children on the liver waiting list requiring retransplantation should have the same access to donor grafts as children requiring a first transplant.


  • Percutaneous Cholecystostomy for Treatment of Acute Cholecystitis in the Era of Early Laparoscopic Cholecystectomy

    by Mehrdad MD Nikfarjam, Lilly Mbbs Shen, Michael A. Mbbs Fink, Vijayaragavan MBBS Muralidharan, Graham Mbbs Starkey, Robert M. MB ChB Jones, Christopher Md Christophi

    Background: Acute cholecystitis is a common surgical problem that is optimally managed by early laparoscopic cholecystectomy when possible. Percutaneous cholecystostomy (PC) has been used in certain high-risk cases as a bridge to surgery or for definitive therapy. The aim of this study was to determine the short-term and long-term outcomes of patients with acute cholecystitis treated by PC. Study Design: Patients with acute cholecystitis treated by PC between 2005 and 2011 in a tertiary hospital were identified from a prospectively maintained database. Outcome differences between patients with acalculous acute cholecystitis (AAC) and those with acute cholecystitis relating to gallstones were determined. Results: There were 32 cases from a total of 443 patients with acute cholecystitis treated by PC during the study period. The overall 30-day mortality rate after PC was 9%. There were 8 patients with AAC in this series. Ischemic heart disease and chronic renal failure were noted in 47% and 41% of patients, respectively. In all cases, patients were considered unfit for surgery. AAC was more common in male patients. In all other aspects patients with AAC had similar characteristics to those with gallstones. Patients underwent percutaneous drainage a median of 3 days after admission with a direct transperitoneal route used in 16 (75%) cases. Positive bile cultures from the gallbladder were noted in 60% of cases tested. Complications were noted in 53% of patients and were related to the cholecystostomy tube in 19% of cases. Subsequent cholecystectomy was performed in 9 (28%) patients, at a median of 73 days after initial tube insertion. No differences in morbidity and mortality were noted between patients with AAC and those with gallstones. The overall mean and 12 months survival was 43 months and 72%, respectively. Hypotension at presentation (odds ratio 9.2; 95% confidence interval, 1.4-59.8; P=0.019) and absence of bile duct filling on cholecystography (odds ratio 4.6; 95% confidence interval, 1.2-16.3; P=0.017) were independently associated with decreased survival. Conclusions: PC can be performed safely in patients considered unfit for surgery at presentation. Outcomes are similar in patients with or without gallstones. Hypotension and absence of common bile duct filling on initial cholangiography are markers of decreased long-term survival. A significant number of patients require subsequent definitive cholecystectomy.